In addition to MAP2K7, other pathways identified as essential for T-ALL cell survival, and potential targets for drug therapy, were also inhibited by 5Z7O such as FOXO3, AKT, AMPK, and MEK [25–29]. Here, AKT1 is linked to acute lymphoblastic leukemia.